Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

ABT US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

ABT US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Abbott Laboratories(ABT US)

$108.52+1.271.18%Ext:$108.75+0.230.21%(After Hours · 00:17:50 UTC)
Ask AI
Doc SearchProfileEntity StructureEDINET FilingsFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Abbott Laboratories(ABT US)

$108.52+1.271.18%Ext:$108.75+0.230.21%(After Hours · 00:17:50 UTC)
Ask AI
Doc SearchProfileEntity StructureEDINET FilingsFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
EDINET Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees
EDINET Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Abbott Laboratories — Company Profile

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UN
CEO
Robert Ford
Headquarters
Abbott Park, IL, US
IPO Date
Mar 17, 1980
Employees
115,000
Website
www.abbott.com

Key Metrics

Price
$97.50

Abbott Laboratories — Company Profile

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UN
CEO
Robert Ford
Headquarters
Abbott Park, IL, US
IPO Date
Mar 17, 1980
Employees
115,000
Website
www.abbott.com

Key Metrics

Price
$97.50
Market Cap
$168.71B
Revenue (TTM)
$12.59B
Net Income (TTM)
$928.00M
EPS (TTM)
0.53
P/E (TTM)
26.88
P/B (TTM)
3.24
Dividend Yield
2.40%
ROE (TTM)
2.07%
ROA (TTM)
0.98%
Operating Margin
16.50%
Beta
0.18

Dividends

Last Dividend
$0.63
Last Yield
0.02%

Summary

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Website
www.abbott.com
Location
Abbott Park, IL, US
Phone224 667 6100
Employees115,000
CEORobert Ford
Sector
Health Care
Industry
Pharmaceuticals
IPO DateMar 17, 1980

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(3.6K)

Expand
  • Form 4Moreland Mary K6 Nov
  • Form 144Moreland Mary K5 Nov
  • 10-QQ3ended 30 Sept 20264 Nov
  • 8-KOther Events21 Oct
  • 8-KResults of Operations and Financial Condition21 Oct
  • Form 4Stratton John G2 Oct
  • Form 4Gonzalez Patricia Paola2 Oct
  • Form 4Conroy Kevin T2 Oct
  • Form 4Ahuja Nita2 Oct
  • Form 4Roman Michael F2 Oct
  • Form 4Conroy Kevin T25 Sep
  • Form 4MCCOY JOHN A. JR.3 Sep
  • Form 4Boudreau Philip P3 Sep
  • Form 144MCCOY JOHN A. JR.2 Sep
  • Form 4Ford Robert B27 Aug
  • Form 144Ford Robert B25 Aug
  • 8-KRegulation FD Disclosure20 Aug
  • Form 4Morrone Louis H.13 Aug
  • Form 144Morrone Louis H.11 Aug
  • 10-QQ2ended 30 Jun 202628 Jul

EDINET Filings(20)

Expand
  • IRExtraordinary Report30 Jul 2025
  • 10-KAnnual Securities Report (2024.01.01-2024.12.31)30 Apr 2025
  • IRExtraordinary Report27 Feb 2025
  • PRSSecurities registration statement15 Dec 2024
  • IRSemi-Annual Report (2024.01.01-2024.12.31)26 Sep 2024
  • IRExtraordinary Report22 Aug 2024
  • PRSSecurities registration statement13 Jun 2024
  • 10-KAnnual Securities Report (2023.01.01-2023.12.31)26 Apr 2024
  • IRExtraordinary Report22 Feb 2024
  • PRSSecurities registration statement14 Dec 2023
  • 10-KAnnual Securities Report (2021.01.01-2021.12.31)27 Apr 2022
  • PRSSecurities registration statement9 Dec 2021
  • PRSSecurities registration statement11 Jun 2021
  • 10-KAnnual Securities Report (2020.01.01-2020.12.31)30 Apr 2021
  • PRSSecurities registration statement22 Dec 2020
  • 10-KAnnual Securities Report (2019.01.01-2019.12.31)29 Apr 2020
  • 10-KAnnual Securities Report (2018.01.01-2018.12.31)25 Apr 2019
  • 10-KAnnual Securities Report (2017.01.01-2017.12.31)27 Apr 2018
  • 10-KAnnual Securities Report (2016.01.01-2016.12.31)28 Apr 2017
  • 10-KAnnual Securities Report (2015.01.01-2015.01.31)27 Apr 2016

News

  • Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?12:16PM
  • CenterBook Partners LP Acquires New Shares in Abbott Laboratories $ABT12 Nov
  • Is Trending Stock Abbott Laboratories (ABT) a Buy Now?11 Nov
  • Can UltiSynq Lead Boost Abbott's Cardiac Rhythm Management Business?11 Nov
  • 3 Legacy Health Care Dividend Stocks That Never Go Out of Style11 Nov
  • Abbott Laboratories $ABT Stock: Allen Investment Management LLC Reduces Stake8 Nov
  • Ashton Thomas Private Wealth LLC Buys 5,216 Shares of Abbott Laboratories $ABT8 Nov
  • 3 Medical Device Stocks That Keep Raising Dividends. One Just Hit 55 Years7 Nov
  • 69 Dividend Champions Ranked By Quality Scores (November 2026)7 Nov
  • Dividend Champion, Contender, And Challenger Highlights: Week of November 86 Nov
  • These 12 stocks are good bets to beat the 10-year Treasury over the next decade4 Nov
  • 99,391 Shares of Abbott Laboratories $ABT Bought by Associated Banc Corp4 Nov
  • Abbott Laboratories $ABT Stock: Heritage Investors Management Corp Trims Holdings3 Nov
  • Abbott Touts Favorable Outcomes In Cardiovascular Device Trials2 Nov
  • Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke2 Nov
  • 2 Safe S&P 500 Healthcare Dividend Stocks Boomers Can Buy and Hold Forever2 Nov
  • Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System1 Nov
  • Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System1 Nov
  • 2 Stocks That Could Quietly Become Big Winners in the Artificial Intelligence (AI) Revolution29 Oct
  • Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease29 Oct

Mentions in Filings

  • … ion is also home to more than 400 major corporate headquarters, including over 30 in the Fortune 500. The largest of such companies include Archer Daniels Midland, Deere, Allstate, AbbVie, United Airlines Holdings, <strong>Abbott Laboratories</strong>, Mondelez International, US Foods Holding Corp., Kraft Heinz, McDonald’s and Exelon. The Chicago area is also home to a number of the nation’s leading research universities, including the University of Chicago, Nort …
    MFB Bancorp, Inc.Abbott Laboratories·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·04:27PM
  • … to 2024. Prior to joining Volkswagen, Mr. Di Si held various key positions in finance, business development, and project management with CNH Global, Fiat Industrial S.p.A., Kimberly-Clark Corporation, Monsanto, and <strong>Abbott Laboratories</strong>. Since 2021, Mr. Di Si has served as a member of the Board of Directors of Copersucar, a global trader of sugar and ethanol. Since 2023, Mr. Di Si has served as an independent member of the Boards of Directors of JH …
    LINDSAY CORPAbbott Laboratories·PRE 14A - Preliminary proxy statement·Q2 27·04:15PM
  • … Vice President, Commercial Development at Peninsula Pharmaceuticals, Inc., a privately held biopharmaceutical company. Earlier in his career, Mr. Katkin held leadership positions at InterMune, Inc., Amgen Inc. and <strong>Abbott Laboratories</strong>. Mr. Katkin has served as a member of the board of directors and Chair of the Board of Eledon Pharmaceuticals, Inc. (“Eledon”) since May 2017 and currently serves as Chair of Eledon’s Nominating and Corporate Govern …
    Werewolf Therapeutics, Inc.Abbott Laboratories·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·12 Nov
  • … ion is also home to more than 400 major corporate headquarters, including over 30 in the Fortune 500. The largest of such companies include Archer Daniels Midland, Deere, Allstate, AbbVie, United Airlines Holdings, <strong>Abbott Laboratories</strong>, Mondelez International, US Foods Holding Corp., Kraft Heinz, McDonald’s and Exelon. The Chicago area is also home to a number of the nation’s leading research universities, including the University of Chicago, Nort …
    MFB Bancorp, Inc.Abbott Laboratories·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·12 Nov
  • … into actionable clinical insights with speed, scale, and consistency. His expertise spans operational leadership, healthcare strategy, mergers and acquisitions, business development, and commercialization. Prior to entering genomics, Travis held leadership positions at GE Healthcare, Robert W. Baird, Jefferies & Company, and <strong>Abbott Laboratories</strong>, developing deep experience in healthcare operations, strategic growth, and corporate development.
    Simplify Genomics, Inc.Abbott Laboratories·EX-99 - C-AR - Annual report (crowdfunding)·12 Nov·12 Nov
  • … 506.56 | ​ | ​ | 10,638 | ​ | | 13 | ​ | V | ​ | Visa, Inc. | ​ | 2.33 | ​ | ​ | 420.31 | ​ | ​ | 5,464 | ​ | | ​ | ​ | ​ | ​ | ***Health Care — 13.84%*** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | | 51 | ​ | ABT | ​ | <strong>Abbott Laboratories</strong> | ​ | 2.33 | ​ | ​ | 107.25 | ​ | ​ | 5,470 | ​ | | 23 | ​ | ABBV | ​ | AbbVie, Inc. | ​ | 2.89 | ​ | ​ | 294.45 | ​ | ​ | 6,772 | ​ | | 25 | ​ | JNJ | ​ | Johnson & Johnson | ​ | 3.02 | ​ | ​ | 283.52 | ​ | ​ | 7,0 …
    Advisors Disciplined Trust 2370Abbott Laboratories·487 - Form 487 - Registration statement (unit investment trusts)·Q4 26·02:49PM

Key Stats

Trading

Px/Chg 1D$97.50 / +0.84%
Prev Close$108.33
% of 52Wk H76.75%
Avg Volume12.46M
Beta0.18
Mkt Cap168.71B
FD Mkt Cap182.59B

Float

Shrs Out/Float1.73B / 1.72B
Short Float0.01%
Days to Cover1.48
Stock Repurchased$180.00M

Current Valuation

EV196.60B
EV/EBITDA17.54
EV/Sales4.36
P/B3.24
P/S3.74
FCF Yield0.54%
ROE2.07%
ROA0.98%
Current Ratio1.39

Dividend

Cash$0.63
Yield2.40%
Yield (TTM)2.40%

Estimates

P/E26.88
Est P/E0.00
Est EPS1.14
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24Apr '25Apr '26Oct '26
PRICE-BASED RATIOS
Price / Earnings70.6328.2632.2116.8692.33183.50
Price / Sales8.464.494.605.3914.3113.52
Price / Book Value4.255.344.774.743.153.27
Price / Free Cash Flow69.0925.1036.4335.5862.44185.90
ENTERPRISE VALUE METRICS
Enterprise Value200,185.5204,198.3193,516.0233,882.6171,159.4198,171.0
Enterprise Value / Sales9.154.684.825.5814.9415.74
Enterprise Value / EBITDA45.7717.1818.2521.5960.65111.21
Enterprise Value / EBIT52.6423.6926.2930.7171.32111.21

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue71.9%43,075.043,653.040,109.041,950.044,328.0
Gross Income1.5%23,214.022,323.020,037.021,325.024,607.0
EBITDA-1.3%12,159.011,888.010,605.010,834.011,553.0
EBIT53.5%8,621.08,621.07,362.07,616.08,807.0
Net Income-2%7,071.06,933.05,723.013,402.06,524.0
EPS (Diluted)-1.4%3.943.913.277.643.72
BALANCE SHEET
Cash & ST Inv-3.4%10,249.010,170.07,279.07,967.08,939.0
Total Assets3.6%75,196.074,438.073,214.081,414.086,713.0
Total Liabilities-3.5%39,172.037,533.034,387.033,513.033,942.0
Total Shareholder Equity9.8%35,802.036,686.038,603.047,664.052,130.0
CASH FLOW
Net Operating Cash Flow-2.4%10,533.09,581.07,261.08,558.09,566.0
Cap Ex3.6%-1,885.0-1,777.0-2,202.0-2,207.0-2,171.0
Free Cash Flow-3.8%8,648.07,804.05,059.06,351.07,395.0

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)108.55
Basic Shares1,730.38
Market Cap187,833.1
Diluted Shares1,738.00
Fully Diluted Shares Outstanding1,738.00
Fully Diluted Market Cap188,659.9
+Consolidated Debt31,159.0
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-4,052.0
−Short-term Investments-246.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest596.0
+Pension Liabilities—
Enterprise Value215,536.1

Segment data

Revenue

by Products and services

  • Medical Devices48%
  • Diagnostic Products20%
  • Nutritional Products19%
  • Established Pharmaceutical Products12%

Revenue

by Geography

  • United States40%
  • Non-us37%
  • D [e]6%
  • C [n]4%
  • I [n]4%

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US

Sanofi

SNY US

Market Cap
$168.71B
Revenue (TTM)
$12.59B
Net Income (TTM)
$928.00M
EPS (TTM)
0.53
P/E (TTM)
26.88
P/B (TTM)
3.24
Dividend Yield
2.40%
ROE (TTM)
2.07%
ROA (TTM)
0.98%
Operating Margin
16.50%
Beta
0.18

Dividends

Last Dividend
$0.63
Last Yield
0.02%

Summary

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Website
www.abbott.com
Location
Abbott Park, IL, US
Phone224 667 6100
Employees115,000
CEORobert Ford
Sector
Health Care
Industry
Pharmaceuticals
IPO DateMar 17, 1980

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(3.6K)

Expand
  • Form 4Moreland Mary K6 Nov
  • Form 144Moreland Mary K5 Nov
  • 10-QQ3ended 30 Sept 20264 Nov
  • 8-KOther Events21 Oct
  • 8-KResults of Operations and Financial Condition21 Oct
  • Form 4Stratton John G2 Oct
  • Form 4Gonzalez Patricia Paola2 Oct
  • Form 4Conroy Kevin T2 Oct
  • Form 4Ahuja Nita2 Oct
  • Form 4Roman Michael F2 Oct
  • Form 4Conroy Kevin T25 Sep
  • Form 4MCCOY JOHN A. JR.3 Sep
  • Form 4Boudreau Philip P3 Sep
  • Form 144MCCOY JOHN A. JR.2 Sep
  • Form 4Ford Robert B27 Aug
  • Form 144Ford Robert B25 Aug
  • 8-KRegulation FD Disclosure20 Aug
  • Form 4Morrone Louis H.13 Aug
  • Form 144Morrone Louis H.11 Aug
  • 10-QQ2ended 30 Jun 202628 Jul

EDINET Filings(20)

Expand
  • IRExtraordinary Report30 Jul 2025
  • 10-KAnnual Securities Report (2024.01.01-2024.12.31)30 Apr 2025
  • IRExtraordinary Report27 Feb 2025
  • PRSSecurities registration statement15 Dec 2024
  • IRSemi-Annual Report (2024.01.01-2024.12.31)26 Sep 2024
  • IRExtraordinary Report22 Aug 2024
  • PRSSecurities registration statement13 Jun 2024
  • 10-KAnnual Securities Report (2023.01.01-2023.12.31)26 Apr 2024
  • IRExtraordinary Report22 Feb 2024
  • PRSSecurities registration statement14 Dec 2023
  • 10-KAnnual Securities Report (2021.01.01-2021.12.31)27 Apr 2022
  • PRSSecurities registration statement9 Dec 2021
  • PRSSecurities registration statement11 Jun 2021
  • 10-KAnnual Securities Report (2020.01.01-2020.12.31)30 Apr 2021
  • PRSSecurities registration statement22 Dec 2020
  • 10-KAnnual Securities Report (2019.01.01-2019.12.31)29 Apr 2020
  • 10-KAnnual Securities Report (2018.01.01-2018.12.31)25 Apr 2019
  • 10-KAnnual Securities Report (2017.01.01-2017.12.31)27 Apr 2018
  • 10-KAnnual Securities Report (2016.01.01-2016.12.31)28 Apr 2017
  • 10-KAnnual Securities Report (2015.01.01-2015.01.31)27 Apr 2016

News

  • Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?12:16PM
  • CenterBook Partners LP Acquires New Shares in Abbott Laboratories $ABT12 Nov
  • Is Trending Stock Abbott Laboratories (ABT) a Buy Now?11 Nov
  • Can UltiSynq Lead Boost Abbott's Cardiac Rhythm Management Business?11 Nov
  • 3 Legacy Health Care Dividend Stocks That Never Go Out of Style11 Nov
  • Abbott Laboratories $ABT Stock: Allen Investment Management LLC Reduces Stake8 Nov
  • Ashton Thomas Private Wealth LLC Buys 5,216 Shares of Abbott Laboratories $ABT8 Nov
  • 3 Medical Device Stocks That Keep Raising Dividends. One Just Hit 55 Years7 Nov
  • 69 Dividend Champions Ranked By Quality Scores (November 2026)7 Nov
  • Dividend Champion, Contender, And Challenger Highlights: Week of November 86 Nov
  • These 12 stocks are good bets to beat the 10-year Treasury over the next decade4 Nov
  • 99,391 Shares of Abbott Laboratories $ABT Bought by Associated Banc Corp4 Nov
  • Abbott Laboratories $ABT Stock: Heritage Investors Management Corp Trims Holdings3 Nov
  • Abbott Touts Favorable Outcomes In Cardiovascular Device Trials2 Nov
  • Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke2 Nov
  • 2 Safe S&P 500 Healthcare Dividend Stocks Boomers Can Buy and Hold Forever2 Nov
  • Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System1 Nov
  • Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System1 Nov
  • 2 Stocks That Could Quietly Become Big Winners in the Artificial Intelligence (AI) Revolution29 Oct
  • Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease29 Oct

Mentions in Filings

  • … ion is also home to more than 400 major corporate headquarters, including over 30 in the Fortune 500. The largest of such companies include Archer Daniels Midland, Deere, Allstate, AbbVie, United Airlines Holdings, <strong>Abbott Laboratories</strong>, Mondelez International, US Foods Holding Corp., Kraft Heinz, McDonald’s and Exelon. The Chicago area is also home to a number of the nation’s leading research universities, including the University of Chicago, Nort …
    MFB Bancorp, Inc.Abbott Laboratories·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·04:27PM
  • … to 2024. Prior to joining Volkswagen, Mr. Di Si held various key positions in finance, business development, and project management with CNH Global, Fiat Industrial S.p.A., Kimberly-Clark Corporation, Monsanto, and <strong>Abbott Laboratories</strong>. Since 2021, Mr. Di Si has served as a member of the Board of Directors of Copersucar, a global trader of sugar and ethanol. Since 2023, Mr. Di Si has served as an independent member of the Boards of Directors of JH …
    LINDSAY CORPAbbott Laboratories·PRE 14A - Preliminary proxy statement·Q2 27·04:15PM
  • … Vice President, Commercial Development at Peninsula Pharmaceuticals, Inc., a privately held biopharmaceutical company. Earlier in his career, Mr. Katkin held leadership positions at InterMune, Inc., Amgen Inc. and <strong>Abbott Laboratories</strong>. Mr. Katkin has served as a member of the board of directors and Chair of the Board of Eledon Pharmaceuticals, Inc. (“Eledon”) since May 2017 and currently serves as Chair of Eledon’s Nominating and Corporate Govern …
    Werewolf Therapeutics, Inc.Abbott Laboratories·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·12 Nov
  • … ion is also home to more than 400 major corporate headquarters, including over 30 in the Fortune 500. The largest of such companies include Archer Daniels Midland, Deere, Allstate, AbbVie, United Airlines Holdings, <strong>Abbott Laboratories</strong>, Mondelez International, US Foods Holding Corp., Kraft Heinz, McDonald’s and Exelon. The Chicago area is also home to a number of the nation’s leading research universities, including the University of Chicago, Nort …
    MFB Bancorp, Inc.Abbott Laboratories·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·12 Nov
  • … into actionable clinical insights with speed, scale, and consistency. His expertise spans operational leadership, healthcare strategy, mergers and acquisitions, business development, and commercialization. Prior to entering genomics, Travis held leadership positions at GE Healthcare, Robert W. Baird, Jefferies & Company, and <strong>Abbott Laboratories</strong>, developing deep experience in healthcare operations, strategic growth, and corporate development.
    Simplify Genomics, Inc.Abbott Laboratories·EX-99 - C-AR - Annual report (crowdfunding)·12 Nov·12 Nov
  • … 506.56 | ​ | ​ | 10,638 | ​ | | 13 | ​ | V | ​ | Visa, Inc. | ​ | 2.33 | ​ | ​ | 420.31 | ​ | ​ | 5,464 | ​ | | ​ | ​ | ​ | ​ | ***Health Care — 13.84%*** | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | | 51 | ​ | ABT | ​ | <strong>Abbott Laboratories</strong> | ​ | 2.33 | ​ | ​ | 107.25 | ​ | ​ | 5,470 | ​ | | 23 | ​ | ABBV | ​ | AbbVie, Inc. | ​ | 2.89 | ​ | ​ | 294.45 | ​ | ​ | 6,772 | ​ | | 25 | ​ | JNJ | ​ | Johnson & Johnson | ​ | 3.02 | ​ | ​ | 283.52 | ​ | ​ | 7,0 …
    Advisors Disciplined Trust 2370Abbott Laboratories·487 - Form 487 - Registration statement (unit investment trusts)·Q4 26·02:49PM

Key Stats

Trading

Px/Chg 1D$97.50 / +0.84%
Prev Close$108.33
% of 52Wk H76.75%
Avg Volume12.46M
Beta0.18
Mkt Cap168.71B
FD Mkt Cap182.59B

Float

Shrs Out/Float1.73B / 1.72B
Short Float0.01%
Days to Cover1.48
Stock Repurchased$180.00M

Current Valuation

EV196.60B
EV/EBITDA17.54
EV/Sales4.36
P/B3.24
P/S3.74
FCF Yield0.54%
ROE2.07%
ROA0.98%
Current Ratio1.39

Dividend

Cash$0.63
Yield2.40%
Yield (TTM)2.40%

Estimates

P/E26.88
Est P/E0.00
Est EPS1.14
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24Apr '25Apr '26Oct '26
PRICE-BASED RATIOS
Price / Earnings70.6328.2632.2116.8692.33183.50
Price / Sales8.464.494.605.3914.3113.52
Price / Book Value4.255.344.774.743.153.27
Price / Free Cash Flow69.0925.1036.4335.5862.44185.90
ENTERPRISE VALUE METRICS
Enterprise Value200,185.5204,198.3193,516.0233,882.6171,159.4198,171.0
Enterprise Value / Sales9.154.684.825.5814.9415.74
Enterprise Value / EBITDA45.7717.1818.2521.5960.65111.21
Enterprise Value / EBIT52.6423.6926.2930.7171.32111.21

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue71.9%43,075.043,653.040,109.041,950.044,328.0
Gross Income1.5%23,214.022,323.020,037.021,325.024,607.0
EBITDA-1.3%12,159.011,888.010,605.010,834.011,553.0
EBIT53.5%8,621.08,621.07,362.07,616.08,807.0
Net Income-2%7,071.06,933.05,723.013,402.06,524.0
EPS (Diluted)-1.4%3.943.913.277.643.72
BALANCE SHEET
Cash & ST Inv-3.4%10,249.010,170.07,279.07,967.08,939.0
Total Assets3.6%75,196.074,438.073,214.081,414.086,713.0
Total Liabilities-3.5%39,172.037,533.034,387.033,513.033,942.0
Total Shareholder Equity9.8%35,802.036,686.038,603.047,664.052,130.0
CASH FLOW
Net Operating Cash Flow-2.4%10,533.09,581.07,261.08,558.09,566.0
Cap Ex3.6%-1,885.0-1,777.0-2,202.0-2,207.0-2,171.0
Free Cash Flow-3.8%8,648.07,804.05,059.06,351.07,395.0

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)108.55
Basic Shares1,730.38
Market Cap187,833.1
Diluted Shares1,738.00
Fully Diluted Shares Outstanding1,738.00
Fully Diluted Market Cap188,659.9
+Consolidated Debt31,159.0
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-4,052.0
−Short-term Investments-246.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest596.0
+Pension Liabilities—
Enterprise Value215,536.1

Segment data

Revenue

by Products and services

  • Medical Devices48%
  • Diagnostic Products20%
  • Nutritional Products19%
  • Established Pharmaceutical Products12%

Revenue

by Geography

  • United States40%
  • Non-us37%
  • D [e]6%
  • C [n]4%
  • I [n]4%

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US

Sanofi

SNY US